C'Estlavie Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 5.00 M
as on 16-11-2024
- Paid Up Capital ₹ 3.00 M
as on 16-11-2024
- Company Age 5 Year, 10 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 9.02 M
as on 16-11-2024
- Revenue 5.01%
(FY 2023)
- Profit 36.43%
(FY 2023)
- Ebitda 4.07%
(FY 2023)
- Net Worth 13.43%
(FY 2023)
- Total Assets -9.15%
(FY 2023)
About C'Estlavie Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 5.00 M and a paid-up capital of Rs 3.00 M.
The company currently has active open charges totaling ₹9.02 M.
Sanjaya Dash and Susama Dash serve as directors at the Company.
- CIN/LLPIN
U74999OR2019PTC030514
- Company No.
030514
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
18 Feb 2019
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Cuttack
Industry
Company Details
- Location
Khorda, Odisha, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at C'Estlavie Pharmaceuticals?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sanjaya Dash  | Managing Director | 18-Feb-2019 | Current |
Board Members(1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Susama Dash | Director | 18-Feb-2019 | Current |
Financial Performance of C'Estlavie Pharmaceuticals.
C'Estlavie Pharmaceuticals Private Limited, for the financial year ended 2023, experienced modest growth in revenue, with a 5.01% increase. The company also saw a substantial improvement in profitability, with a 36.43% increase in profit. The company's net worth Soared by an impressive increase of 13.43%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of C'Estlavie Pharmaceuticals?
In 2023, C'Estlavie Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
State Bank Of India Creation Date: 07 Nov 2020 | ₹3.50 M | Open |
State Bank Of India Creation Date: 03 Jun 2020 | ₹3.02 M | Open |
State Bank Of India Creation Date: 05 Jul 2019 | ₹2.50 M | Open |
How Many Employees Work at C'Estlavie Pharmaceuticals?
C'Estlavie Pharmaceuticals has a workforce of 16 employees as of Apr 01, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of C'Estlavie Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped C'Estlavie Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
